PressAugust 3, 2022 PSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Third Consecutive Month
PressAugust 3, 2022 Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
PressAugust 3, 2022 Braxia Scientific Enters U.S. Telemedicine Industry; Acquires KetaMD, a Mental Health Platform Providing Beneficial Ketamine Treatments in Florida with plans to expand across the U.S.
BlogAugust 3, 2022 Cody Shandraw Invests in Entrepreneurs Obsessed with Impacting and Improving Lives – Psychedelic Investors #1
PressAugust 3, 2022 Kaya Holdings to Seek Licenses for First Ever State Legal Psilocybin Manufacturing and Facilitation Service Centers in Oregon
LifestyleAugust 2, 2022 Many Counties Are Voting To Opt Out – But That Doesn’t Mean The End Of Measure 109
PressAugust 2, 2022 COMPASS Pathways to participate in upcoming BTIG Biotechnology Conference and Canaccord Annual Growth Conference
PressAugust 2, 2022 atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
PressAugust 2, 2022 Unlimited Sciences Announces Groundbreaking New Study to Observe Ayahuasca’s Effects on Trauma
PressJuly 28, 2022 Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement
PressJuly 28, 2022 Hemplucid Becomes First Startup to Provide Psychedelic Therapy as Employee Healthcare Benefit
PressJuly 28, 2022 U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation
PressJuly 28, 2022 Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
PressJuly 28, 2022 COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
PressJuly 27, 2022 Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth
